Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment

  1. Hideo Hagihara author has email address
  2. Hirotaka Shoji
  3. Satoko Hattori
  4. Giovanni Sala
  5. Yoshihiro Takamiya
  6. Mika Tanaka
  7. Masafumi Ihara
  8. Mihiro Shibutani
  9. Izuho Hatada
  10. Kei Hori
  11. Mikio Hoshino
  12. Akito Nakao
  13. Yasuo Mori
  14. Shigeo Okabe
  15. Masayuki Matsushita
  16. Anja Urbach
  17. Yuta Katayama
  18. Akinobu Matsumoto
  19. Keiichi I. Nakayama
  20. Shota Katori
  21. Takuya Sato
  22. Takuji Iwasato
  23. Haruko Nakamura
  24. Yoshio Goshima
  25. Matthieu Raveau
  26. Tetsuya Tatsukawa
  27. Kazuhiro Yamakawa
  28. Noriko Takahashi
  29. Haruo Kasai
  30. Johji Inazawa
  31. Ikuo Nobuhisa
  32. Tetsushi Kagawa
  33. Tetsuya Taga
  34. Mohamed Darwish
  35. Hirofumi Nishizono
  36. Keizo Takao
  37. Kiran Sapkota
  38. Kazutoshi Nakazawa
  39. Tsuyoshi Takagi
  40. Haruki Fujisawa
  41. Yoshihisa Sugimura
  42. Kyosuke Yamanishi
  43. Lakshmi Rajagopal
  44. Nanette Deneen Hannah
  45. Herbert Y. Meltzer
  46. Tohru Yamamoto
  47. Shuji Wakatsuki
  48. Toshiyuki Araki
  49. Katsuhiko Tabuchi
  50. Tadahiro Numakawa
  51. Hiroshi Kunugi
  52. Freesia L. Huang
  53. Atsuko Hayata-Takano
  54. Hitoshi Hashimoto
  55. Kota Tamada
  56. Toru Takumi
  57. Takaoki Kasahara
  58. Tadafumi Kato
  59. Isabella A. Graef
  60. Gerald R. Crabtree
  61. Nozomi Asaoka
  62. Hikari Hatakama
  63. Shuji Kaneko
  64. Takao Kohno
  65. Mitsuharu Hattori
  66. Yoshio Hoshiba
  67. Ryuhei Miyake
  68. Kisho Obi-Nagata
  69. Akiko Hayashi-Takagi
  70. Léa J. Becker
  71. Ipek Yalcin
  72. Yoko Hagino
  73. Hiroko Kotajima-Murakami
  74. Yuki Moriya
  75. Kazutaka Ikeda
  76. Hyopil Kim
  77. Bong-Kiun Kaang
  78. Hikari Otabi
  79. Yuta Yoshida
  80. Atsushi Toyoda
  81. Noboru H. Komiyama
  82. Seth G. N. Grant
  83. Michiru Ida-Eto
  84. Masaaki Narita
  85. Ken-ichi Matsumoto
  86. Emiko Okuda-Ashitaka
  87. Iori Ohmori
  88. Tadayuki Shimada
  89. Kanato Yamagata
  90. Hiroshi Ageta
  91. Kunihiro Tsuchida
  92. Kaoru Inokuchi
  93. Takayuki Sassa
  94. Akio Kihara
  95. Motoaki Fukasawa
  96. Nobuteru Usuda
  97. Tayo Katano
  98. Teruyuki Tanaka
  99. Yoshihiro Yoshihara
  100. Michihiro Igarashi
  101. Takashi Hayashi
  102. Kaori Ishikawa
  103. Satoshi Yamamoto
  104. Naoya Nishimura
  105. Kazuto Nakada
  106. Shinji Hirotsune
  107. Kiyoshi Egawa
  108. Kazuma Higashisaka
  109. Yasuo Tsutsumi
  110. Shoko Nishihara
  111. Noriyuki Sugo
  112. Takeshi Yagi
  113. Naoto Ueno
  114. Tomomi Yamamoto
  115. Yoshihiro Kubo
  116. Rie Ohashi
  117. Nobuyuki Shiina
  118. Kimiko Shimizu
  119. Sayaka Higo-Yamamoto
  120. Katsutaka Oishi
  121. Hisashi Mori
  122. Tamio Furuse
  123. Masaru Tamura
  124. Hisashi Shirakawa
  125. Daiki X. Sato
  126. Yukiko U. Inoue
  127. Takayoshi Inoue
  128. Yuriko Komine
  129. Tetsuo Yamamori
  130. Kenji Sakimura
  131. Tsuyoshi Miyakawa author has email address
  1. Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Aichi 470-1192, Japan
  2. Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Osaka 564-8565, Japan
  3. Laboratory of Genome Science, Biosignal Genome Resource Center, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma 371-8512, Japan
  4. Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan
  5. Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Kyoto 615-8510, Japan
  6. Department of Cellular Neurobiology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
  7. Department of Molecular and Cellular Physiology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan
  8. Hans Berger Department of Neurology, Jena University Hospital, Jena D07747, Germany
  9. Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka 812-8582, Japan
  10. Laboratory of Mammalian Neural Circuits, National Institute of Genetics, Mishima, Shizuoka 411-8540, Japan
  11. Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan
  12. Laboratory for Neurogenetics, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
  13. Department of Neurodevelopmental Disorder Genetics, Institute of Brain Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan
  14. Laboratory of Structural Physiology, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
  15. Department of Physiology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan
  16. International Research Center for Neurointelligence (WPI-IRCN), UTIAS, The University of Tokyo, Tokyo 113-0033, Japan
  17. Research Core Center, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
  18. Department of Stem Cell Regulation, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
  19. Department of Behavioral Physiology, Graduate School of Innovative Life Science, University of Toyama, Toyama, Toyama 930-0194, Japan
  20. Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
  21. Medical Research Institute, Kanazawa Medical University, Uchinada, Kahoku, Ishikawa920-0293, Japan
  22. Life Science Research Center, University of Toyama, Toyama, Toyama 930-0194, Japan
  23. Department of Neuroscience, Southern Research, Birmingham, AL 35205, USA
  24. Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi 480-0392, Japan
  25. Department of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, Toyoake, Aichi 470-1192, Japan
  26. Department of Neuropsychiatry, Hyogo Medical University, School of Medicine, Nishinomiya, Hyogo 663-8501, Japan
  27. Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
  28. Department of Molecular Neurobiology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa 761-0793, Japan
  29. Department of Peripheral Nervous System Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan
  30. Department of Molecular & Cellular Physiology, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621, Japan
  31. Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan
  32. Department of Psychiatry, Teikyo University School of Medicine, Tokyo 173-8605, Japan
  33. Program of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institute of Health, Bethesda, MD 20892, USA
  34. Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan
  35. Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka 565-0871, Japan
  36. United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Osaka 565-0871, Japan
  37. Division of Bioscience, Institute for Datability Science, Osaka University, Suita, Osaka 565-0871, Japan
  38. Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka 565-0871, Japan
  39. Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan
  40. RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan
  41. Department of Physiology and Cell Biology, Kobe University School of Medicine, Kobe, Hyogo 650-0017, Japan
  42. Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
  43. Institute of Biology and Environmental Sciences, Carl von Ossietzky University of Oldenburg, Oldenburg 26129, Germany
  44. Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
  45. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  46. Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602-8566, Japan
  47. Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto 606-8501, Japan
  48. Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan
  49. Laboratory of Medical Neuroscience, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma 371-8512, Japan
  50. Laboratory for Multi-scale Biological Psychiatry, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
  51. Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Université de Strasbourg, Strasbourg 67000, France
  52. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
  53. Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul 08826, South Korea
  54. College of Agriculture, Ibaraki University, Ami, Ibaraki 300-0393, Japan
  55. United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8538, Japan
  56. Ibaraki University Cooperation between Agriculture and Medical Science (IUCAM), Ami, Ibaraki 300-0393, Japan
  57. Genes to Cognition Program, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
  58. Simons Initiative for the Developing Brain, Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh EH8 9XF, UK
  59. Department of Developmental and Regenerative Medicine, Mie University, Graduate School of Medicine, Tsu, Mie 514-8507, Japan
  60. Department of Biosignaling and Radioisotope Experiment, Interdisciplinary Center for Science Research, Organization for Research and Academic Information, Shimane University, Izumo, Shimane 693-8501, Japan
  61. Department of Biomedical Engineering, Osaka Institute of Technology, Osaka 535-8585, Japan
  62. Department of Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700-8530, Japan
  63. Child brain project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
  64. Division for Therapies Against Intractable Diseases, Center for Medical Science, Fujita Health University, Toyoake, Aichi 470-1192, Japan
  65. Research Center for Idling Brain Science, University of Toyama, Toyama, Toyama 930-0194, Japan
  66. Department of Biochemistry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Toyama 930-0194, Japan
  67. Core Research for Evolutionary Science and Technology (CREST), Japan Science and Technology Agency (JST), University of Toyama, Toyama, Toyama 930-0194, Japan
  68. Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan
  69. Department of Anatomy II, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan
  70. Department of Medical Chemistry, Kansai Medical University, Hirakata, Osaka 573-1010, Japan
  71. Department of Developmental Medical Sciences, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
  72. Laboratory for Systems Molecular Ethology, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
  73. Department of Neurochemistry and Molecular Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951-8510, Japan
  74. Transdiciplinary Research Program, Niigata University, Niigata, Niigata 951-8510, Japan
  75. Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8566, Japan
  76. Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8572, Japan
  77. Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8572, Japan
  78. Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Fujisawa, Kanagawa 251-8555, Japan
  79. Department of Genetic Disease Research, Osaka City University Graduate School of Medicine, Osaka, Osaka 545-8585, Japan
  80. Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
  81. Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan
  82. Glycan & Life Systems Integration Center (GaLSIC), Soka University, Tokyo 192-8577, Japan
  83. Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka 565-0871, Japan
  84. National Institute for Basic Biology, Laboratory of Morphogenesis, Okazaki, Aichi 444-8585, Japan
  85. Division of Biophysics and Neurobiology, National Institute for Physiological Sciences, Okazaki, Aichi 444-8585, Japan
  86. Laboratory of Neuronal Cell Biology, National Institute for Basic Biology, Okazaki, Aichi 444-8585, Japan
  87. Department of Basic Biology, SOKENDAI (Graduate University for Advanced Studies), Okazaki, Aichi 444-8585, Japan
  88. Exploratory Research Center on Life and Living Systems (ExCELLS), Okazaki, Aichi 444-8585, Japan
  89. Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo 113-0033, Japan
  90. Healthy Food Science Research Group, Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8566, Japan
  91. Department of Applied Biological Science, Graduate School of Science and Technology, Tokyo University of Science, Noda, Chiba 278-8510, Japan
  92. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-8562, Japan
  93. School of Integrative and Global Majors (SIGMA), University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
  94. Department of Molecular Neuroscience, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Toyama 930-0194, Japan
  95. Technology and Development Team for Mouse Phenotype Analysis, Japan Mouse Clinic, RIKEN BioResource Research Center (BRC), Tsukuba, Ibaraki 305-0074, Japan
  96. Graduate School of Life Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan
  97. Young Researcher Support Group, Research Enhancement Strategy Office, National Institute for Basic Biology, National Institute of Natural Sciences, Okazaki, Aichi 444-8585, Japan
  98. Division of Brain Biology, National Institute for Basic Biology, Okazaki, Aichi 444-8585, Japan
  99. Laboratory for Molecular Analysis of Higher Brain Function, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
  100. Department of Cellular Neurobiology, Brain Research Institute, Niigata University, Niigata, Niigata 951-8585, Japan
  101. Department of Animal Model Development, Brain Research Institute, Niigata University, Niigata, Niigata 951-8585, Japan

Peer review process

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, and public reviews.

Read more about eLife’s peer review process.

Editors

  • Reviewing Editor
    Michelle Antoine
    National Institute on Alcohol Abuse and Alcoholism, Bethesda, United States of America
  • Senior Editor
    Sacha Nelson
    Brandeis University, Waltham, United States of America

Reviewer #1 (Public Review):

Summary
In this manuscript, Hagihara et al. characterized the relationship between the changes in lactate and pH and the behavioral phenotypes in different animal models of neuropsychiatric disorders at a large-scale level. The authors have previously reported that increased lactate levels and decreased pH are commonly observed in the brains of five genetic mouse models of schizophrenia (SZ), bipolar disorder (BD), and autism spectrum disorder (ASD). In this study, they expanded the detection range to 109 strains or conditions of animal models, covering neuropsychiatric disorders and neurodegenerative disorders. Through statistical analysis of the first 65 strains/conditions of animal models which were set as exploratory cohort, the authors found that most strains showed decreased pH and increased lactate levels in the brains. There was a significant negative correlation between pH and lactate levels both at the strain/condition level and the individual animal level. Besides, only working memory was negatively correlated with brain lactate levels. These results were successfully duplicated by studying the confirmative cohort, including 44 strains/conditions of animal models. In all strains/conditions, the lactate levels were not correlated with age, sex, or storage duration of brain samples.

Strengths
1. The manuscript is well-written and structured. In particular, the discussion is really nice, covering many potential mechanisms for the altered lactate levels in these disease models.
2. Tremendous efforts were made to recruit a huge number of various animal models, giving the conclusions sufficient power.

Weaknesses
1. The biggest concern of this study is the limited novelty. The point of "altered pH and/or lactate levels in the brains from human and rodent animals of neuropsychiatric disorders" has been reported by the same lab and other groups in many previous papers.
2. This study is mostly descriptive, lacking functional investigations. Although a larger cohort of animal models were studied which makes the conclusion more solid, limited conceptual advance is contributed to the relevant field, as we are still not clear about what the altered levels of pH and lactate mean for the pathogenesis of neuropsychiatric disorders.
3. The experiment procedure is also a concern. The brains from animal models were acutely collected without cardiac perfusion in this study, which suggests that resident blood may contaminate the brain samples. The lactate is enriched in the blood, making it a potential confounded factor to affect the lactate levels as well as pH in the brain samples.
4. The lactate and pH levels may also be affected by other confounded factors, such as circadian period, and locomotor activity before the mice were sacrificed. This should also be discussed in the paper.
5. Another concern is the animal models. Although previous studies have demonstrated that dysfunctions of these genes could cause related phenotypes for certain disorders, many of them are not acknowledged by the field as reliable disease models. Besides, gene deficiency could also cause many known or unknown unrelated phenotypes, which may contribute to the altered levels of lactate and pH, too. In this circumstance, the conclusion "pH and lactate levels are transdiagnostic endophenotype of neuropsychiatric disorders" is somewhat overstated.
6. The negative correlationship between pH and lactate is rather convincing. However, how much the contribution of lactate to pH is not tested. In addition, regarding pH and lactate, which factor contributes most to the pathogenesis of neuropsychiatric disorders is also unclear. These questions may need to be addressed in the future study.
7. The authorship is open to question. Most authors listed in this paper may only provide mice strains or brain samples. Maybe it is better just to acknowledge them in the acknowledgments section.
8. The last concern is about the significance of this study. Although the majority of strains showed increased lactate, some still showed decreased lactate levels in the brains. These results suggested that lactate or pH is an endophenotype for neuropsychiatric disorders, but it is hard to serve as a good diagnostic index as the change is not unidirectional in different disorders. In other words, the relationship between lactate level and neuropsychiatric disorders is not exclusive.

Reviewer #2 (Public Review):

Hagihara et al. conducted a study investigating the correlation between decreased brain pH, increased brain lactate, and poor working memory. They found altered brain pH and lactate levels in animal models of neuropsychiatric and neurodegenerative disorders. Their study suggests that poor working memory performance may predict higher brain lactate levels.

However, the study has some significant limitations. One major concern is that the authors examined whole-brain pH and lactate levels, which might not fully represent the complexity of disease states. Different brain regions and cell types may have distinct protein and metabolite profiles, leading to diverse disease outcomes. For instance, certain brain regions like the hippocampus and nucleus accumbens exhibit opposite protein/signaling pathways in neuropsychiatric disease models.

Moreover, the memory tests used in the study are specific to certain brain regions, but the authors did not measure lactate levels in those regions. Without making lactate measurements in brain-regions and cell types involved in these diseases, any conclusions regarding the role of lactate in CNS diseases is premature.

Additionally, evidence suggests that exogenous treatment with lactate has positive effects, such as antidepressant effects in multiple disease models (Carrard et al., 2018, Carrard et al., 2021, Karnib et al., 2019, Shaif et al., 2018). It also promotes learning, memory formation, neurogenesis, and synaptic plasticity (Suzuki et al., 2011, Yang et al., 2014, Weitian et al., 2015, Dong et al., 2017, El Hayek et al. 2019, Wang et al., 2019, Lu et al., 2019, Lev-Vachnish et a.l, 2019, Descalzi G et al., 2019, Herrera-López et al., 2020, Ikeda et al., 2021, Zhou et al., 2021,Roumes et al., 2021, Frame et al., 2023, Akter et al., 2023).

In conclusion, the relevance of total brain pH and lactate levels as indicators of the observed correlations is controversial, and evidence points towards lactate having more positive rather than negative effects. It is important that the authors perform studies looking at brain-region-specific concentrations of lactate and that they modulate lactate levels (decrease) in animal models of disease to validate their conclusions. it is also important to consider the above-mentioned studies before concluding that "altered brain pH and lactate levels are rather involved in the underlying pathophysiology of some patients with neuropsychiatric disorders" and that "lactate can serve as a potential therapeutic target for neuropsychiatric disorders".

  1. Howard Hughes Medical Institute
  2. Wellcome Trust
  3. Max-Planck-Gesellschaft
  4. Knut and Alice Wallenberg Foundation